Featured Research

from universities, journals, and other organizations

Breakthrough for type 2 diabetes treatment: Therapy involves the blockade of signalling by VEGF-B protein

Date:
September 27, 2012
Source:
Karolinska Institutet
Summary:
An international team of scientists has discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

An international team of scientists, led from Karolinska Institutet in Sweden, has discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

In experiments on mice and rats, the scientists have managed to both prevent the development of type II diabetes and reverse the progression of established disease. The study is published in the journal Nature, where it is described as a breakthrough in diabetes research. The findings are the result of a joint effort by Karolinska Institutet, the Ludwig Institute for Cancer Research and the Australian biopharmaceutical company CSL Limited, amongst others.

"It's a great feeling to present these results," says Professor Ulf Eriksson of the Department of Medical Biochemistry and Biophysics at Karolinska Institutet. "We discovered VEGF-B back in 1995, and since then the VEGF-B project has been a lengthy sojourn in the wilderness, but now we're making one important discovery after the other. In this present study we've shown that VEGF-B inhibition can be used to prevent and treat type II diabetes, and that this can be done with a drug candidate."

Type II diabetes is normally preceded by insulin resistance caused by obesity. When this happens, the cells no longer respond sufficiently to insulin, which leads to elevated levels of blood sugar. Insulin resistance is related to the storage of fat in the 'wrong' places, such as the muscles, blood vessels and heart, although exactly how this relationship works is not fully known.

What scientists do know, however, is that the VEGF-B protein affects the transport and storage of fat in body tissue. This was discovered by Professor Ulf Eriksson's research group in a study published in Nature in 2010. These theories have now been developed for a new study in which VEGF-B signalling was blocked in a group of diabetic mice and rats.

A total of four related studies are reported in the Nature paper. In one case, mice bred to spontaneously develop diabetes were given a drug candidate called 2H10, which is an antibody that blocks the effect of VEGF-B. The mice subsequently developed neither insulin resistance, nor diabetes. The team also crossed the diabetes strain of mice with one that lacked the ability to produce VEGF-B, and found that the offspring were protected from developing the disease.

In another two studies, the scientists took normal mice and rats that had not been specially bread to develop type II diabetes, and left them to develop the disease as a result of a fat-rich diet and the resulting obesity. In these cases, progression of the established disease was halted and reversed to varying degrees after treatment with 2H10.

"The results we present in this study represent a major breakthrough and an entirely new principle for the prevention and treatment of type II diabetes," says Professor Åke Sjöholm, consultant in diabetology at Stockholm South General Hospital. "Existing treatments can cause many adverse reactions and their effects normally wear off. There is a desperate need for new treatment strategies for type II diabetes."

Current treatments for type II diabetes normally involve initial dietary measures and/or pills designed to boost insulin secretion and sensitivity or to reduce glucose production. After a few years, such treatments eventually prove inadequate for up to 30 per cent of patients, who then require insulin injections. Type II diabetes is reaching epidemic proportions, and according to the World Health Organisation, is expected to afflict over half a billion people by 2030.

The drug candidate used in the study, 2H10, is a monoclonal antibody and is being developed by the biopharmaceutical company CSL Limited. Scientists from CSL contributed to the work and the company co-funded the study. Funding was also supplied by the Ludwig Institute for Cancer Research, the Frans Wilhelm and Waldemar von Frenckell Fund, the Wilhelm and Else Stockmann Foundation, the Novo Nordisk Foundation, the Swedish Cancer Society, the Swedish Research Council, the Torsten and Ragnar Söderberg Foundations, the Research Foundation of the Swedish Diabetes Association (Diabetesfonden), the Peter Wallenberg Foundation for Economics and Technology, and the Swedish Heart-Lung Foundation.

Earlier this year, Professor Eriksson was awarded the Heart-Lung Foundation's grand research grant of SEK 15 million (about € 1.7 million / $ 2.3 million) the largest in Sweden in the field of cardiovascular disease. The grant will be used to finance further research into VEGF-B.


Story Source:

The above story is based on materials provided by Karolinska Institutet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Carolina E. Hagberg, Annika Mehlem, Annelie Falkevall, Lars Muhl, Barbara C. Fam, Henrik Ortsäter, Pierre Scotney, Daniel Nyqvist, Erik Samén, Li Lu, Sharon Stone-Elander, Joseph Proietto, Sofianos Andrikopoulos, Åke Sjöholm, Andrew Nash, Ulf Eriksson. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature, 2012; DOI: 10.1038/nature11464

Cite This Page:

Karolinska Institutet. "Breakthrough for type 2 diabetes treatment: Therapy involves the blockade of signalling by VEGF-B protein." ScienceDaily. ScienceDaily, 27 September 2012. <www.sciencedaily.com/releases/2012/09/120927091526.htm>.
Karolinska Institutet. (2012, September 27). Breakthrough for type 2 diabetes treatment: Therapy involves the blockade of signalling by VEGF-B protein. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2012/09/120927091526.htm
Karolinska Institutet. "Breakthrough for type 2 diabetes treatment: Therapy involves the blockade of signalling by VEGF-B protein." ScienceDaily. www.sciencedaily.com/releases/2012/09/120927091526.htm (accessed August 20, 2014).

Share This




More Health & Medicine News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) — Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com
101-Year-Old Working Man Has All The Advice You Need

101-Year-Old Working Man Has All The Advice You Need

Newsy (Aug. 19, 2014) — Herman Goldman has worked at the same lighting store for almost 75 years. Find out his secrets to a happy, productive life. Video provided by Newsy
Powered by NewsLook.com
Researcher Testing on-Field Concussion Scanners

Researcher Testing on-Field Concussion Scanners

AP (Aug. 19, 2014) — Four Texas high school football programs are trying out an experimental system designed to diagnose concussions on the field. The technology is in response to growing concern over head trauma in America's most watched sport. (Aug. 19) Video provided by AP
Powered by NewsLook.com
American Ebola Patient Apparently Improving, Outbreak Is Not

American Ebola Patient Apparently Improving, Outbreak Is Not

Newsy (Aug. 19, 2014) — Nancy Writebol, an American missionary who contracted Ebola, is apparently getting better, according to her husband. The outbreak, however, is not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins